NCT04634513View on ClinicalTrials.gov

Shigella CVD 31000: Study of Responses with Shigella-ETEC Vaccine Strain CVD 1208S-122

PHASE1CompletedINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

September 29, 2022

Primary Completion Date

October 1, 2024

Study Completion Date

October 1, 2024

Conditions
Shigella InfectionEnterotoxigenic Escherichia Coli Infection
Interventions
BIOLOGICAL

strain CVD 1208S-122

Live, attenuated, vaccine strain of S. flexneri 2a expressing CFA/I and LT of enterotoxigenic E. coli

OTHER

Placebo

Sodium bicarbonate buffer

Trial Locations (1)

21201

University of Maryland, Baltimore, University of Maryland School of Medicine, Center for Vaccine Development and Global Health, Baltimore

All Listed Sponsors
lead

University of Maryland, Baltimore

OTHER